PFE

27.4000.51%
CB

Chris Boshoff

Chief Scientific Officer and President of Research & Development

Dr. Chris Boshoff, M.D., FRCP, FMedSci, Ph.D, serves as Chief Scientific Officer and President oF Research & Development of Pfizer Inc. since January 1, 2025 and was its Chief Oncology Officer since December 15, 2023 until January 1, 2025 and served as its Executive Vice President since July 27, 2023 until January 1, 2025. He served as Chief Development Officer of Oncology and Rare Disease at Pfizer Inc. until July 27, 2023 and served as its Chief Oncology Research and Development Officer and Executive Vice President from July 2023 until December 15, 2023 and served as its Senior Vice President and Head of Immuno-Oncology, Translational Oncology & Early Development and Chief Development Officer of Global Product Development Oncology. Dr. Boshoff is Professor of Cancer Medicine at UCLH. Dr. Boshoff serves as Director of the UCL Cancer Institute. He served as a Non-Executive Director of Advanced Oncotherapy Plc from March 18, 2013 to October 25, 2013. He has published extensively in peer reviewed journals including Nature, Lancet Oncology and The New England Journal of Medicine. He trained in Medicine in South Africa and specialised in Medical Oncology at the Royal London, Royal Free, Royal Marsden and University College London Hospitals. He completed a PhD in Viral Oncology at the Institute of Cancer Research, London. He is a Fellow of the Royal College of Physicians (FRCP) and a Fellow of the Academy of Medical Sciences (FMedSci).

公司职务